Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study

Research output: Contribution to journalLetterResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{4a3ab7d6144448edad3c83a0891aa420,
title = "Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study",
abstract = "Highlights This population-based real-world prescription study characterized all new users of liraglutide in northern Denmark from 2009 to 2015. More than half (57{\%}) the patients had liraglutide prescribed as part of drug combinations outside the originally approved indications. Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73{\%} of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1-5 trials that led to liraglutide registration, underscoring the need for further post-marketing studies.",
keywords = "cross-sectional studies, diabetes pharmacology, drug utilization, glucagon-like peptide-1 receptor, liraglutide, cross-sectional studies, diabetes pharmacology, drug utilization, glucagon-like peptide-1 receptor, liraglutide",
author = "Knudsen, {Jakob S} and Thomsen, {Reimar W} and Anton Potteg{\aa}rd and Knop, {Filip K} and S{\o}rensen, {Henrik T}",
note = "{\circledC} 2019 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.",
year = "2019",
month = "8",
doi = "10.1111/1753-0407.12919",
language = "English",
volume = "11",
pages = "690--694",
journal = "Journal of Diabetes",
issn = "1753-0393",
publisher = "Wiley-Blackwell Publishing, Inc",
number = "8",

}

RIS

TY - JOUR

T1 - Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark

T2 - a routine clinical care prescription study

AU - Knudsen, Jakob S

AU - Thomsen, Reimar W

AU - Pottegård, Anton

AU - Knop, Filip K

AU - Sørensen, Henrik T

N1 - © 2019 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

PY - 2019/8

Y1 - 2019/8

N2 - Highlights This population-based real-world prescription study characterized all new users of liraglutide in northern Denmark from 2009 to 2015. More than half (57%) the patients had liraglutide prescribed as part of drug combinations outside the originally approved indications. Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73% of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1-5 trials that led to liraglutide registration, underscoring the need for further post-marketing studies.

AB - Highlights This population-based real-world prescription study characterized all new users of liraglutide in northern Denmark from 2009 to 2015. More than half (57%) the patients had liraglutide prescribed as part of drug combinations outside the originally approved indications. Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73% of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1-5 trials that led to liraglutide registration, underscoring the need for further post-marketing studies.

KW - cross-sectional studies

KW - diabetes pharmacology

KW - drug utilization

KW - glucagon-like peptide-1 receptor

KW - liraglutide

KW - cross-sectional studies

KW - diabetes pharmacology

KW - drug utilization

KW - glucagon-like peptide-1 receptor

KW - liraglutide

UR - http://www.scopus.com/inward/record.url?scp=85065042871&partnerID=8YFLogxK

U2 - 10.1111/1753-0407.12919

DO - 10.1111/1753-0407.12919

M3 - Letter

VL - 11

SP - 690

EP - 694

JO - Journal of Diabetes

JF - Journal of Diabetes

SN - 1753-0393

IS - 8

ER -

ID: 57062355